M&A

Can Sanofi push a CVR on Actelion after the Lemtrada fiasco?

The buzz this morning is that Sanofi $SNY is moving ahead steadily on working out a deal to buy Actelion. And Bloomberg reports that the pharma giant has brought out its favorite M&A tool — the CVR, or contingent value right shares — to get the job done without handing over too large a premium.

Sanofi observers will well remember that the CVR is what clinched the $20 billion deal for Genzyme. But those CVRs are now trading at 38 cents after Sanofi, not known for a very effective in-house R&D group, failed to hit any of the big milestones it laid out for investors. Originally valued at $5.58, or $3.8 billion, the CVR {GCVRZ} was built around Lemtrada, which was initially rejected by the FDA, derailing the commercialization timeline. And that rejection was followed up with a lawsuit.

The drug was finally approved in late 2014 and went on to post disappointing 2015 sales, further damaging the CVR.

Jean-Paul Clozel

Jean-Paul Clozel

Nevertheless, Bloomberg reports that a CVR may be just what Actelion CEO Jean-Paul Clozel needs to give up his well known preference for independence. Clozel has seen off several would-be suitors and activist investment groups pushing a sale. J&J $JNJ was the last to go a few days ago, officially signing out of the deal room but reportedly keeping an eye on the progress Sanofi makes on a buyout that could weigh in around $30 billion.

One reason why Sanofi would prefer a CVR is that Clozel has been the company’s biggest pipeline fan. He is particularly pumped about the MS drug ponesimod — a sphingosine-1-phosphate 1 receptor agonist — just as Genzyme’s Henri Termeer was pumped about Lemtrada. Sanofi is also well past its $20 billion self-imposed limitation on new acquisitions, which will further add to the attractiveness of a CVR. But after losing Medivation to Pfizer, Sanofi CEO Olivier Brandicourt needs to produce a deal to help appease investors as its diabetes franchise wanes.

Sanofi’s bleak CVR past, current R&D effort — as distinct from its collaborations with Regeneron — and troubled future are likely to keep Clozel focused on the cash. The pharma giant’s promises on research and CVRs look pretty thin at this stage.


The best place to read Endpoints News? In your inbox.

Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

EvaluatePharma World Preview 2017